Potential SP Valuation of AT1 - 80 cents to 1.30/share, page-961

As I do more research and study the Market that ATOMOS is part of, I get more excited specially in these volatile times. They seems to have the best product by far see below much bigger companies Alere and Accubiotech. Both of these companies have a rapid test for HIV but it seems that you need a lab or a professional to to the test.
https://www.alere.com/en/home/product-details/determine-hiv-1-2.html
https://www.accubiotech.com/product-covid-19-igg-igm-rapid-test-cassette-(whole-blood-serum-plasma).html


Atomos on the other hand has easy to use and individuals can, if they want can do this at home (similar to a pregnancy test or diabetic levels).

So, we have established that the product is better/easy to use. I would go as far as to say this looks like an iPhone of Rapid Test market .

Secondly, how big the self test market. According to Atomo's Prospectus
"The global lateralflow assay market recorded revenues ofUS$4.57 billion in 2019.2 In 2018 it wasestimated that 54% of the global lateralflow assay market related to medicaltesting with the rest being environmentand food testing. 3Atomo’s initial focus wascommercialisation of solutions for HIVtesting. Atomo believes that prioritisingsolutions for HIV testing has the greatestimpact on society and has the potentialto underpin the success of the Company.Atomo is also focused on the sale of rapidtest devices to OEM customers.Information on the Company’s currentproducts and development pipeline is setout in Section 2. These includea) HIV rapid test products(i) HIV Professional Use tests forhealthcare professionals;(ii) HIV Self Tests for consumers;(b) OEM rapid test products utilisingAtomo’s Pascal rapid test devices(i) Blood-based pregnancy tests forprofessional use;(ii) Blood-based pregnancy self-testsfor lay users;(iii) Antimicrobial resistance (AMR)screening tests for professionaluse; and(iv)HIV professional use tests fordeployment in LMICs." It seems that Atomos is working on product extension, they started with HIV self test and plan to roll out Blood based pregnancy.

To sum up the $AT1 pricing does not factor the growth potential. They are on their way to do 3-4x revenue in FY 2020 vs FY 2019 (COVID-19 testing kit not factored). COVID-19 is a huge opportunity, if they can do more partnerships like "NG BIO TECH", with companies in US, China or India they can become the premium Rapid Testing Brand. Australia is know for quality products and I think people will pay extra for easy to use and quality Rapid Test.